The stars are aligning for it to be a leader for years to come. With a gene therapy for two illnesses out the door, and with sales slated to take off over the next few quarters, CRISPR Therapeutics (CRSP -1.28%) is making it a good time to be a shareholder. But could this biotech's halcyon days be so good that a $10,000 investment today could end up being worth millions of dollars? Although such returns may seem wild, history is full of many such wealth-generating events. Let's dive in and explore if invest ...

These biotech stocks have just launched their first products. The stock market is roaring higher, with the Nasdaq and S&P 500 recently extending gains to reach new record highs. But don't worry. It's not too late to get in on this market growth. The indexes confirmed their presence in a bull market earlier this year, but these phases of market optimism tend to last quite some time -- and history shows us they generally go on for much longer than bear markets. In a study spanning 1926 through 2017, the avera ...

The gene-editing therapy specialist is rising in prominence. CRISPR Therapeutics (CRSP -2.27%) is a star in the gene-editing therapy niche. The company made tremendous progress over the past few years, culminating in its first regulatory approval -- for Casgevy, a therapy for the rare blood diseases transfusion-dependent beta-thalassemia and sickle cell disease. Though that was an important milestone for the biotech, CRISPR Therapeutics remains unprofitable, and it is unlikely to launch another product in t ...

业绩总结 - CRISPR Therapeutics AG 去年与合作伙伴 Vertex 公司获得了 CASGEVY 的批准，这款产品在商业上取得了良好的开端[2] - CRISPR Therapeutics AG 目前在临床阶段有五个项目，涵盖了肿瘤学、自身免疫疾病、心血管疾病、罕见病和糖尿病等领域[3] - CRISPR Therapeutics AG 计划在未来五年内每年至少推出两个新项目，展示了公司科学引擎的高效生产力[5] 新产品和新技术研发 - CRISPR Therapeutics AG 的 CAR T 疗法在肿瘤学和自身免疫疾病领域表现出色，展示了潜在的治疗优势[10] - CRISPR Therapeutics AG 的 ALAS1 项目针对急性肝性卟啉病，展示了在模型中的潜在疗效[23] - CRISPR Therapeutics AG 的 AGT 项目和 ALAS1 项目进一步拓展了公司的疾病治疗范围，覆盖了常见和罕见疾病[13] - CRISPR Therapeutics AG 的新项目 340 针对高血压患者，展示了潜在的降压效果，为治疗难治性高血压和抗药性高血压提供新途径[18] - CRISPR Therapeutics AG 的 Allogeneic CAR T 项目展示了在自身免疫疾病领域的潜在应用，为持久缓解提供可能性[28] 市场扩张和并购 - CASGEVY 的成功推出对整个行业具有标志性意义，受到广泛关注，预计通过有针对性的条件化将市场扩大至少三倍以上[6] 其他新策略和有价值的信息 - 公司在自身的研究中发现，使用lenti治疗自身免疫疾病存在二次恶性肿瘤的风险，因此需要更严格的审查[30] - 公司认为自身的CAR Ts和NK细胞比其他同类产品更具潜力和效力[30] - 公司在糖尿病领域有三个并行项目，其中CTX211是世界首个进入人体试验的编辑干细胞衍生产品[33]

How much would you pay for a stock that might earn $25 a year in six years? CRISPR Therapeutics (CRSP 2.26%) closed last week down 8.5% after reporting first-quarter "earnings" results that looked a lot more like losses. Lacking a big milestone payment like the one in Q1 2023, CRISPR's revenue plummeted 99.5% year over year, and the company reported a per-share loss of $1.43 -- more than twice the year-ago loss. And that's OK -- at least according to Oppenheimer analyst Jay Olson, who on Friday lowered his ...

These healthcare stocks offer completely different approaches to long-term investment gains. Your long-term investment portfolio should have meaningful exposure to healthcare stocks. People will always seek treatments for disease, so demand for the sector won't go away any time soon. Moreover, there's a wide variety of healthcare companies, making it an attractive sector for any type of investor. Consider how this value stock and this growth stock below might enhance your portfolio. 1. Pfizer Pfizer (PFE -0 ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month, shares of this company have returned -15.7%, compared to the Zacks S&P 500 composite's +1.3% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which CRISPR Therapeutics falls in, has gained 0.8%. The key question now is: What could be the stock's fu ...

As investors, we are always aiming to reevaluate our portfolios and make additions. However, we can often get lost in the vastness of the markets when deciding on just a handful of companies. A great place to solve this dilemma is by looking at what other investors are choosing. What better place to start than looking for the best Cathie Wood stocks to buy? After all, she is one of the most famous and respected investors. If she has done the work of rigorously analyzing these companies to put into the holdi ...

CRISPR Therapeutics (CRSP) reported earnings of $1.43 per share in the first quarter of 2024, surpassing the Zacks Consensus Estimate of a loss of $1.63. In the year-ago period, the company had incurred a loss of 67 cents per share. The company’s total revenues, generated entirely from grant revenues, were $0.5 million in the first quarter. The reported figures significantly missed the Zacks Consensus Estimate of $8.3 million. In the year-ago quarter, the company generated revenues worth $100 million, which ...

ZUG, Switzerland and BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, at 12:20 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's ...